Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Deferred Revenue: 2023-2024

Historic Current Deferred Revenue for Entrada Therapeutics (TRDA) over the last 2 years, with Dec 2024 value amounting to $13.7 million.

  • Entrada Therapeutics' Current Deferred Revenue fell 99.24% to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $351,000, marking a year-over-year decrease of 99.24%. This contributed to the annual value of $13.7 million for FY2024, which is 89.68% down from last year.
  • Per Entrada Therapeutics' latest filing, its Current Deferred Revenue stood at $13.7 million for FY2024, which was down 89.68% from $132.3 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Current Deferred Revenue registered a high of $132.3 million during FY2023, and its lowest value of $13.7 million during FY2024.
  • Its 2-year average for Current Deferred Revenue is $73.0 million, with a median of $73.0 million in 2023.
  • Data for Entrada Therapeutics' Current Deferred Revenue shows a maximum YoY tumbled of 89.68% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Current Deferred Revenue (Yearly) stood at $132.3 million in 2023, then slumped by 89.68% to $13.7 million in 2024.